Single centre clinical experience with fidaxomicin in the treatment of Clostridium difficile infection in Slovakia
Language English Country Czech Republic Media print
Document type Journal Article
PubMed
30817879
DOI
10.21101/cejph.a5476
Knihovny.cz E-resources
- Keywords
- Clostridium difficile infection, fidaxomicin treatment, recurrence,
- MeSH
- Anti-Bacterial Agents therapeutic use MeSH
- Clostridioides difficile drug effects isolation & purification MeSH
- Child MeSH
- Adult MeSH
- Fidaxomicin therapeutic use MeSH
- Clostridium Infections diagnosis drug therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Slovakia epidemiology MeSH
- Names of Substances
- Anti-Bacterial Agents MeSH
- Fidaxomicin MeSH
OBJECTIVE: Clostridium difficile infection (CDI) has become one of the most common causes of hospital-acquired infections. Fidaxomicin is one of the latest antibiotics used in the treatment of CDI, however, treatment cost affects recommendations for its use in several countries. We have analysed the treatment of our patients with CDI, treated by fidaxomicin since it was introduced to the market in 2018 and became available in the second biggest Slovak hospital, University Hospital of L. Pasteur. Our aim was to determine efficacy and safety of fidaxomicin in the treatment of CDI in Slovak patients. METHODS: We reviewed all courses of fidaxomicin use in our hospital (n = 60). Fidaxomicin was used for first recurrence (12 times), second recurrence (4 times), third recurrence (2 times), and fifth recurrence (1 patient). 41 patients received fidaxomicin first-line. RESULTS: Success of fidaxomicin treatment was recorded at 86.7% within the whole cohort. In the recurrent Clostridium difficile infection (rCDI) subgroup, fidaxomicin was 63% effective with three patients dying (15.7%) and two patients developing subsequent rCDI. During the duration of the study, 6 patients in total died. Only one of three patients, with three or more recurrences of CDI, had no further presentations after eight weeks of completion of treatment. CONCLUSIONS: The biggest benefit from fidaxomicin treatment was shown in a cohort of patients with primary CDI infection demonstrating a low recurrence rate and significant reduction of fidaxomicin effectiveness in preventing a recurrence when treating patients with multiple rCDI.
References provided by Crossref.org
